BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
2.12.2024 03:05:00 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / December 2, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, announces the development of a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, internally identified as BNT24005. This innovative product is intended to address limitations of existing administration methods for a therapeutic developed by Novo Nordisk, with the aim of improving patient accessibility and convenience. This product is currently under development and remains subject to regulatory review and approval.
Semaglutide: A Proven Therapeutic Leader
Semaglutide, developed by Novo Nordisk and marketed under brand names such as Ozempic® and Wegovy®, has revolutionized treatment for Type 2 diabetes and obesity. By mimicking glucagon-like peptide-1 (GLP-1), it enhances insulin secretion, reduces appetite, and slows gastric emptying, offering powerful tools for glycemic control and weight management.
In 2023, Semaglutide generated over $14 billion in revenue globally, reflecting surging demand for effective diabetes and obesity treatments (The Washington Post).
The BioNxt Advantage
Despite Semaglutide's success, its injectable format presents barriers, including needle anxiety and challenges with long-term adherence. BioNxt's sublingual thin-film technology, BNT24005, offers a novel delivery system that aims to reduce these hurdles, improving the overall patient experience.
Key benefits of the sublingual thin-film include:
Needle-Free Convenience: A painless and discreet alternative to injections.
Rapid Absorption: Direct sublingual delivery for faster therapeutic action.
Enhanced Bioavailability: Reduced enzymatic degradation compared to traditional oral routes.
Improved Patient Compliance: A portable, user-friendly format designed to encourage long-term adherence.
This next-generation delivery method has the potential to address unmet needs in diabetes and obesity care, aligning with global trends favoring patient-centric solutions.
Significant Market Opportunity
The global burden of diabetes and obesity underscores the growing need for innovative treatments. According to the International Diabetes Federation, over 537 million adults worldwide are living with diabetes, and the prevalence of obesity continues to rise.
Semaglutide's existing market success highlights the potential for innovative delivery systems. BioNxt aims to address patient challenges while adhering to stringent regulatory and intellectual property standards.
Strategic Development and Patent Positioning
BioNxt's thin-film innovation focuses on enhancing drug delivery methods without infringing on existing molecule patents. The product leverages a strategy centered on patentable administration improvements, respecting the intellectual property of Novo Nordisk.
BioNxt's Broader Pipeline of Innovations
The Semaglutide thin-film, BNT24005, is part of BioNxt's broader portfolio of advanced drug delivery technologies, targeting therapeutic areas such as neurodegenerative diseases, metabolic disorders, and other high-need markets. BioNxt's platforms include sublingual thin-films, transdermal patches, and enteric-coated oral tablets, all designed to enhance patient outcomes and healthcare accessibility.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements regarding the development, potential benefits, and commercialization of BioNxt's sublingual thin-film product for Semaglutide. These statements are based on current expectations and projections about future events but involve risks and uncertainties outside of the Company's control. Risks include challenges in obtaining regulatory approvals, potential intellectual property disputes or claims from third parties, and uncertainties associated with product development, manufacturing, and clinical validation. Additional risks include the potential for limited market acceptance of the sublingual thin-film technology and competitive pressures within the diabetes and obesity therapeutic sectors. Readers are cautioned that actual results may differ materially from those expressed in these forward-looking statements due to these and other factors. BioNxt Solutions Inc. undertakes no obligation to update forward-looking statements, except as required by applicable laws.
Trademarks: Trademarks Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S and are referenced in this document solely for informational and comparative purposes to contextualize the market landscape. BioNxt Solutions Inc. is neither affiliated with nor endorsed by Novo Nordisk A/S.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
New GTDC Research Details Distribution's Influence on AI, Cloud and Hyperscaler Sales and Adoption3.3.2026 16:00:00 CET | Press release
IT distributors have become digital ecosystem orchestrators that unify cloud, AI, hyperscaler, and subscription-based business models. Distribution significantly accelerates vendor growth while reducing risk, allowing suppliers to scale efficiently, expand partner bases, enter new markets and mitigate financial and operational liabilities. Digital platforms are creating a new GTM "operating system". These systems offer end-to-end digital commerce and intelligence layers to manage procurement, billing, lifecycles and analytics. TAMPA, FL / ACCESS Newswire / March 3, 2026 / The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, has released a new research report, Distribution: The Digital Force Multiplier. Developed by CommCentric Solutions, this study examines how IT distribution has transformed and continues to evolve into a critical enabler of cloud, artificial intelligence (AI), hyperscaler and platform-driven business models acr
Datavault AI Reports Significant Institutional Ownership Growth as Platform Expansion Accelerates3.3.2026 14:08:00 CET | Press release
PHILADELPHIA, PA / ACCESS Newswire / March 3, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real‑world asset tokenization technologies, today highlighted a marked increase in institutional ownership alongside continued commercial expansion across media and enterprise markets. Between the fourth quarter of 2025 and February 2026, several major asset managers significantly expanded their positions in Datavault AI. According to recent public filings, Vanguard increased its holdings from approximately 393,000 shares to 11.8 million shares. State Street expanded from roughly 335,000 shares to 10.0 million shares. BlackRock increased its position from approximately 136,000 shares to 4.1 million shares. These changes represent percentage increases of approximately 2,900%, 2,800%, and 3,000%, respectively. Management views this increase in institutional participation as support for Datavault AI'
AccessPay Partners With PayPoint to Strengthen Fraud and Error Prevention for Corporate Payments3.3.2026 10:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / March 3, 2026 / AccessPay, the leading bank integration provider, today announced a new partnership with PayPoint to integrate PayPoint's Confirmation of Payee (CoP) capability into AccessPay's payments automation suite for modern finance teams. With £258m lost to authorised push payment (APP) fraud in the first half of 2025 alone, organisations need access to robust payment controls that scale with their operations.1 PayPoint's CoP offering enables AccessPay's customers to verify payee account details as part of their payment workflows, reinforcing AccessPay's position at the centre of a growing ecosystem of technologies designed to automate and de-risk the Office of the CFO. CoP, also known as Account Name Verification (ANV), is a valuable anti-fraud measure that checks the accuracy of payee details before funds are sent. It can be used to confirm payee details at the point of collection, when creating a payment instruction, or both. PayPoint's CoP
Affiliate of Pacific Avenue Capital Partners to Acquire Care.com from IAC3.3.2026 01:00:00 CET | Press release
LOS ANGELES, CA / ACCESS Newswire / March 2, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a Los Angeles-headquartered private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced that an affiliate of Pacific Avenue has entered into an agreement to acquire Care.com from IAC Inc. (NASDAQ:IAC). Care.com is a leading platform and brand in the growing $400 billion market for family care, anchored by the largest online network of background-checked child and senior caregivers in the U.S. Care.com operates both a scaled consumer marketplace and an enterprise benefits platform. Since 2007, more than 45 million people have turned to Care.com to find child care, senior care, pet care and housekeeping support. Care.com also partners with more than 700 employers, including many of the Fortune 100, to deliver care-related benefits that combine access to the Care.com platform and comprehensive backup care solutions provided in
Stagwell Launches Stagwell Search+: The Industry's First Agentic Platform To Win AI Search2.3.2026 14:30:00 CET | Press release
New media solution enables brands to win discoverability, visibility, positive sentiment, and outcomes across major AI systems NEW YORK, NY AND LONDON, UK / ACCESS Newswire / March 2, 2026 / Stagwell (NASDAQ:STGW), the global challenger network transforming marketing through AI, today announced the global launch of Stagwell Search+, the industry's first agentic platform for AI Search experiences. Built by Assembly, Stagwell's global omnichannel media agency, in partnership with Emberos, the operating system for AI visibility, Stagwell Search+ is a category-defining solution to master the transition from traditional search engines to AI search experiences. As Large Language Models (LLMs) increasingly mediate how people discover, compare, and choose, Stagwell Search+ helps brands optimize not just for clicks and traffic, but for a new era of search where AI guides decisions and the goal is to be chosen. The solution combines an agentic platform with a differentiated framework that improv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom